Lakefront Biotherapeutics (LKFT) Income from Discontinued Operations (2020 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Income from Discontinued Operations for 4 consecutive years, with 80572093.17 the latest figure, recorded in Q4 2024.

• In Q4 2024, Income from Discontinued Operations fell 65.28% year-over-year to 80572093.17; the TTM figure through Dec 2024 stood at 338832510.1 (up 31.2% YoY), while the FY2024 annual figure was 80572093.17, down 65.28% from the prior year.
• Income from Discontinued Operations fell to 80572093.17 in Q4 2024 per LKFT's latest filing, from 232080238.37 in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at 232080238.37 in Q4 2023 and bottomed at 1876696.34 in Q1 2020.
• Historically, Income from Discontinued Operations has averaged 62065595.42 across 4 years, with a median of 26479310.11 in 2021.
• Annual changes were most pronounced in 2021 — Income from Discontinued Operations surged 1326.89% — and 2024, when it slumped 65.28%.
• Lakefront Biotherapeutics' Income from Discontinued Operations stood at 4905924.39 in 2020, then surged by 433.64% to 26180178.56 in 2021, then jumped by 786.47% to 232080238.37 in 2023, then plunged by 65.28% to 80572093.17 in 2024.
• Business Quant data shows LKFT's Income from Discontinued Operations at 80572093.17 in Q4 2024, 232080238.37 in Q4 2023, and 26180178.56 in Q3 2021.